The BLV receptor candidate gene has been localized precisely on cattle, goat, and sheep chromosomes using nonradioactive in situ hybridization and simultaneous fluorescent R-banding. The probe, a whole plasmid containing a 2.3-kb bovine cDNA fragment encoding part of this gene, was nick-translated in the presence of biotin-11-dUTP. It hybridized on band q15 of cattle chromosome 7, goat chromosome 7, and sheep chromosome 5, thus confirming the homoeology based on banding patterns among the chromosomes of these three species.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000133936 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of combined cytotoxic T-lymphocyte antigen 4 and programed death 1 ligand-receptor blockade on interferon-gamma production in bovine leukemia virus-infected cattle.
Vet World
August 2024
Laboratory of Immunochemistry and Immunobiotechnology, National Center for Biotechnology, Astana, Kazakhstan.
Background And Aim: In chronic viral infections, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death ligand 1 (PD-L1) significantly suppress immune responses. The CTLA-4 receptor abundance in regulatory T cells showed a positive association with viral load and a negative association with interferon-gamma (IFN-γ) production in bovine leukemia virus (BLV)-infected cattle. Blocking this receptor boosted IFN-γ production, recovering immune response against this illness.
View Article and Find Full Text PDFSMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer.
Cell Death Dis
June 2024
Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016, Chongqing, China.
Article Synopsis
- - Endocrine resistance is a major issue for patients with hormone receptor-positive, HER2-negative breast cancer, often linked to dysregulation of estrogen receptor (ER) and ERBB signaling pathways, though how these pathways interact is not fully understood.
- - The study investigates SMAD4's role in this resistance, finding that lower SMAD4 levels in breast cancer tissues correlate with poor patient outcomes, and that its depletion triggers resistance to endocrine therapy by enhancing ER and ERBB signaling.
- - The results suggest that targeting SMAD4 alongside ER, ERBB, and autophagy pathways could offer a new treatment approach for patients facing endocrine resistance in HR+ HER2- breast cancer.
Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
Clin Drug Investig
July 2024
Shiraz University of Medical Sciences, Janbazan Blv, 14th Alley, Jahrom, Shiraz, 7417773539, Fars, Iran.
Article Synopsis
- Standard schizophrenia treatment primarily relies on antipsychotic medications targeting D2 dopamine receptors, which can have limitations and adverse effects like motor impairments and sedation.
- KarXT is a new treatment combining xanomeline, which activates certain brain receptors to improve symptoms, with trospium, which reduces side effects by affecting peripheral receptors without crossing the blood-brain barrier.
- Initial clinical trials show KarXT may significantly improve symptoms and cognitive function in schizophrenia patients, but more research is needed to fully determine its effectiveness and safety.
Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.
Nat Commun
March 2024
Institute of Molecular Biology and Biophysics, ETH Zürich, Zürich, Switzerland.
Cellular entry of the hepatitis B and D viruses (HBV/HDV) requires binding of the viral surface polypeptide preS1 to the hepatobiliary transporter Na-taurocholate co-transporting polypeptide (NTCP). This interaction can be blocked by bulevirtide (BLV, formerly Myrcludex B), a preS1 derivative and approved drug for treating HDV infection. Here, to elucidate the basis of this inhibitory function, we determined a cryo-EM structure of BLV-bound human NTCP.
View Article and Find Full Text PDFSerological and Molecular Investigation of SARS-CoV-2 in Horses and Cattle in Switzerland from 2020 to 2022.
Viruses
January 2024
Clinical Laboratory, Vetsuisse Faculty, Department of Clinical Diagnostics and Services, and Center for Clinical Studies, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland.
Horses and cattle have shown low susceptibility to SARS-CoV-2, and there is no evidence of experimental intraspecies transmission. Nonetheless, seropositive horses in the US and seropositive cattle in Germany and Italy have been reported. The current study investigated the prevalence of antibodies against SARS-CoV-2 in horses and cattle in Switzerland.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!